Neurocrine Biosciences reported results for the 2026 quarter with revenue of $959M and diluted EPS of $1.39, driven by product launches and volume growth that supported higher net income versus the prior-year quarter.Financial Highlights¹ Reported as “Total revenues”. ² Reported as “Net income”. ³…
Q2 2026 revenue grew 39% year-over-year to $959M, with strong sales from INGREZZA, CRENESSITY, and VYKAT XR. Non-GAAP net income rose 79% to $297M, and 2026 guidance for INGREZZA net sales was raised. The Soleno acquisition and pipeline expansion position the company for continued growth.Original d…
Guggenheim reiterated a Buy on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and lifted its price target to $200, while the company promoted Samir Siddhanti to Chief Business Officer to drive growth, BD, corporate strategy and maximize pipeline value.Previous Week RecapThis is an AI-generated summary…
SAN DIEGO, July 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Samir Siddhanti as Chief Business Officer and a member of the company's executive Management Committee.As Chief Business Officer, Siddhanti will lead Neurocrine's enterprise growt…
Neurocrine Biosciences, Inc NASDAQ:NBIX:
Neurocrine Biosciences NBIX) has quietly become one of biotech's strongest earnings stories, combining impressive commercial execution with a rapidly improving profit outlook.While many biotechnology companies remain years away from consistent profitability, Neurocrine has established itself as a c…
For Immediate ReleaseChicago, IL – June 29, 2026 – Zacks Equity Research shares Neurocrine Biosciences NBIX as the Bull of the Day and Ryanair Holdings RYAAY as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Netflix NFLX, Amazon.com, Inc. AMZN and The Walt Disney Co. D…
